Matinas BioPharma Holdings, Inc. (MTNB)
NYSEAMERICAN: MTNB · Real-Time Price · USD
0.5905
-0.0295 (-4.76%)
May 2, 2025, 4:00 PM EDT - Market closed

Company Description

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology.

The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.

Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy.

It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium.

The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead’s remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations.

Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings logo
Country United States
Founded 2013
Industry Biotechnology
Sector Healthcare
Employees 3
CEO Jerome Jabbour

Contact Details

Address:
1545 Route 206 South, Suite 302
Bedminster, New Jersey 07921
United States
Phone 908 484 8805
Website matinasbiopharma.com

Stock Details

Ticker Symbol MTNB
Exchange NYSEAMERICAN
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001582554
CUSIP Number 576810105
ISIN Number US5768101058
Employer ID 46-3011414
SIC Code 2834

Key Executives

Name Position
Jerome D. Jabbour J.D. Co-Founder, Chief Executive Officer and Chairman
Frank Calamusa Executive Director and Head of Manufacturing and Supply Chain

Latest SEC Filings

Date Type Title
May 2, 2025 8-K Current Report
Apr 29, 2025 EFFECT Notice of Effectiveness
Apr 29, 2025 ARS Filing
Apr 29, 2025 424B3 Prospectus
Apr 22, 2025 S-3 Registration statement under Securities Act of 1933
Apr 15, 2025 10-K Annual Report
Apr 10, 2025 SCHEDULE 13D/A Filing
Apr 10, 2025 SCHEDULE 13D/A Filing
Apr 8, 2025 8-K Current Report
Apr 4, 2025 8-K Current Report